BioCentury
ARTICLE | Clinical News

Genentech reports Phase I data for MPDL3280A

May 16, 2013 12:56 AM UTC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said IV MPDL3280A once every three weeks led to an objective response rate (ORR) of 21% in 140 patients with locally advanced or metastatic solid tumors whose disease had progressed despite prior therapy in an open-label Phase I trial. Responders included patients with non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), colorectal cancer and gastric cancer.

In patients with PD-L1-positive tumors (n=36), MPDL3280A led to an ORR of 36% compared to an ORR of 13% in patients with PD-L1-negative tumors (n=67). However, Genentech said a PD-L1 diagnostic is still "evolving" and that a negative result on the PD-L1 test could mean that tumors have less PD-L1 than the test can currently detect. Data are slated to be presented at the American Society of Clinical Oncology meeting in June. ...